A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms RISE
- Sponsors Teva Branded Pharmaceutical Products R&D
- 08 Mar 2019 Planned End Date changed from 27 Apr 2020 to 26 Apr 2020.
- 08 Mar 2019 Planned primary completion date changed from 28 Jan 2020 to 27 Jan 2020.
- 03 May 2018 Planned End Date changed from 30 Oct 2019 to 27 Apr 2020.